# HeartBeam, Inc.: financial statements, quarterly

BEATW · Nasdaq · CIK 1779372 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/beatw.md) · [Financials](/companies/beatw/financials.md) · [Filings](/companies/beatw/filings.md) · [Insiders](/companies/beatw/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/beatw/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Research and development | $k | [1,623](/filings/0001628280-24-046250.md) | [2,010 d](/filings/0001628280-25-012614.md) | [2,428](/filings/0001628280-25-025064.md) | [2,844](/filings/0001628280-25-040135.md) | [2,893](/filings/0001193125-25-280112.md) | [2,886 d](/filings/0001193125-26-104080.md) | [3,492](/filings/0001193125-26-221565.md) | [3,326](/filings/0001193125-26-349121.md) | [3,278](/filings/0001193125-25-280112.md) | [3,354 d](/filings/0001193125-26-104080.md) | [2,370](/filings/0001193125-26-221565.md) | [2,328](/filings/0001193125-26-349121.md) |
| Selling, general and administrative | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating income | $k | [(3,737)](/filings/0001628280-24-046250.md) | [(4,109) d](/filings/0001628280-25-012614.md) | [(4,784)](/filings/0001628280-25-025064.md) | [(5,090)](/filings/0001628280-25-040135.md) | [(5,069)](/filings/0001193125-25-280112.md) | [(4,944) d](/filings/0001193125-26-104080.md) | [(5,504)](/filings/0001193125-26-221565.md) | [(5,037)](/filings/0001193125-26-349121.md) | [(5,290)](/filings/0001193125-25-280112.md) | [(5,310) d](/filings/0001193125-26-104080.md) | [(4,716)](/filings/0001193125-26-221565.md) | [(5,092)](/filings/0001193125-26-349121.md) |
| Interest expense | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $k | [0.0](/filings/0001628280-24-046250.md) | [0.0 d](/filings/0001628280-25-012614.md) | [0.0](/filings/0001628280-25-025064.md) | [0.0](/filings/0001628280-25-040135.md) | [0.0](/filings/0001193125-25-280112.md) | [0.0 d](/filings/0001193125-26-104080.md) | [0.0](/filings/0001193125-26-221565.md) | [0.0](/filings/0001193125-26-349121.md) | [0.0](/filings/0001193125-25-280112.md) | [0.0 d](/filings/0001193125-26-104080.md) | [0.0](/filings/0001193125-26-221565.md) | [0.0](/filings/0001193125-26-349121.md) |
| Net income | $k | [(3,470)](/filings/0001628280-24-046250.md) | [(3,879) d](/filings/0001628280-25-012614.md) | [(4,606)](/filings/0001628280-25-025064.md) | [(4,956)](/filings/0001628280-25-040135.md) | [(4,979)](/filings/0001193125-25-280112.md) | [(4,907) d](/filings/0001193125-26-104080.md) | [(5,484)](/filings/0001193125-26-221565.md) | [(4,974)](/filings/0001193125-26-349121.md) | [(5,255)](/filings/0001193125-25-280112.md) | [(5,302) d](/filings/0001193125-26-104080.md) | [(4,700)](/filings/0001193125-26-221565.md) | [(5,039)](/filings/0001193125-26-349121.md) |
| Diluted EPS | $ per share | [(0.13)](/filings/0001628280-24-046250.md) | not reported | [(0.17)](/filings/0001628280-25-025064.md) | [(0.19)](/filings/0001628280-25-040135.md) | [(0.19)](/filings/0001193125-25-280112.md) | not reported | [(0.18)](/filings/0001193125-26-221565.md) | [(0.15)](/filings/0001193125-26-349121.md) | [(0.15)](/filings/0001193125-25-280112.md) | not reported | [(0.12)](/filings/0001193125-26-221565.md) | [(0.10)](/filings/0001193125-26-349121.md) |
| Basic EPS | $ per share | [(0.13)](/filings/0001628280-24-046250.md) | not reported | [(0.17)](/filings/0001628280-25-025064.md) | [(0.19)](/filings/0001628280-25-040135.md) | [(0.19)](/filings/0001193125-25-280112.md) | not reported | [(0.18)](/filings/0001193125-26-221565.md) | [(0.15)](/filings/0001193125-26-349121.md) | [(0.15)](/filings/0001193125-25-280112.md) | not reported | [(0.12)](/filings/0001193125-26-221565.md) | [(0.10)](/filings/0001193125-26-349121.md) |

- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: not reported
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [19.2](/filings/0001628280-24-046250.md) | [16.2](/filings/0001628280-25-012614.md) | [12.6](/filings/0001628280-25-025064.md) | [9.2](/filings/0001628280-25-040135.md) | [5.8](/filings/0001193125-25-280112.md) | [2.4](/filings/0001193125-26-104080.md) | [4.4](/filings/0001193125-26-221565.md) | [3.3](/filings/0001193125-26-349121.md) | [1.9](/filings/0001193125-25-280112.md) | [4.4](/filings/0001193125-26-349121.md) | [2.0](/filings/0001193125-26-221565.md) | [8.7](/filings/0001193125-26-349121.md) |
| Current assets | $m | [19.5](/filings/0001779372-23-000034.md) | [16.8](/filings/0001628280-25-012614.md) | [13.2](/filings/0001779372-24-000006.md) | [9.7](/filings/0001628280-24-037202.md) | [6.1](/filings/0001628280-24-046250.md) | [2.8](/filings/0001193125-26-104080.md) | [8.6](/filings/0001628280-25-025064.md) | [5.4](/filings/0001628280-25-040135.md) | [2.1](/filings/0001193125-25-280112.md) | [4.7](/filings/0001193125-26-349121.md) | [2.4](/filings/0001193125-26-221565.md) | [9.0](/filings/0001193125-26-349121.md) |
| Total assets | $m | [19.6](/filings/0001779372-23-000034.md) | [17.1](/filings/0001628280-25-012614.md) | [13.6](/filings/0001779372-24-000006.md) | [10.1](/filings/0001628280-24-037202.md) | [6.7](/filings/0001628280-24-046250.md) | [3.3](/filings/0001193125-26-104080.md) | [9.1](/filings/0001628280-25-025064.md) | [6.0](/filings/0001628280-25-040135.md) | [2.9](/filings/0001193125-25-280112.md) | [5.8](/filings/0001193125-26-349121.md) | [3.9](/filings/0001193125-26-221565.md) | [10.6](/filings/0001193125-26-349121.md) |
| Current liabilities | $m | not reported | [1.2](/filings/0001628280-24-046250.md) | not reported | [1.4](/filings/0001628280-24-037202.md) | [1.9](/filings/0001628280-24-046250.md) | [1.6](/filings/0001193125-25-280112.md) | [1.6](/filings/0001628280-25-025064.md) | [1.8](/filings/0001628280-25-040135.md) | [2.5](/filings/0001193125-25-280112.md) | [3.2](/filings/0001193125-26-349121.md) | [3.3](/filings/0001193125-26-221565.md) | [2.5](/filings/0001193125-26-349121.md) |
| Total liabilities | $m | [1.0](/filings/0001779372-23-000034.md) | [1.2](/filings/0001628280-25-012614.md) | [1.1](/filings/0001779372-24-000006.md) | [1.4](/filings/0001628280-24-037202.md) | [1.9](/filings/0001628280-24-046250.md) | [1.6](/filings/0001193125-26-104080.md) | [1.6](/filings/0001628280-25-025064.md) | [1.8](/filings/0001628280-25-040135.md) | [2.5](/filings/0001193125-25-280112.md) | [3.2](/filings/0001193125-26-349121.md) | [3.3](/filings/0001193125-26-221565.md) | [2.5](/filings/0001193125-26-349121.md) |
| Shareholders' equity | $m | [18.6](/filings/0001628280-24-046250.md) | [15.9](/filings/0001193125-26-104080.md) | [12.5](/filings/0001628280-25-040135.md) | [8.7](/filings/0001193125-25-280112.md) | [4.8](/filings/0001193125-25-280112.md) | [1.7](/filings/0001193125-26-349121.md) | [7.5](/filings/0001193125-26-349121.md) | [4.2](/filings/0001193125-26-349121.md) | [0.4](/filings/0001193125-25-280112.md) | [2.6](/filings/0001193125-26-349121.md) | [0.6](/filings/0001193125-26-349121.md) | [8.2](/filings/0001193125-26-349121.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(2,098) d](/filings/0001628280-24-046250.md) | [(2,858) d](/filings/0001628280-25-012614.md) | [(3,463)](/filings/0001628280-25-025064.md) | [(3,550) d](/filings/0001628280-25-040135.md) | [(3,306) d](/filings/0001193125-25-280112.md) | [(4,152) d](/filings/0001193125-26-104080.md) | [(4,477)](/filings/0001193125-26-221565.md) | [(3,445) d](/filings/0001193125-26-349121.md) | [(3,160) d](/filings/0001193125-25-280112.md) | [(2,906) d](/filings/0001193125-26-104080.md) | [(3,610)](/filings/0001193125-26-221565.md) | [(3,342) d](/filings/0001193125-26-349121.md) |
| Capital expenditure | $k | [144 d](/filings/0001628280-24-046250.md) | [112 d](/filings/0001628280-25-012614.md) | [88.0](/filings/0001628280-25-025064.md) | [10.0 d](/filings/0001628280-25-040135.md) | [103 d](/filings/0001193125-25-280112.md) | [0.0 d](/filings/0001193125-26-104080.md) | [0.0](/filings/0001193125-26-221565.md) | [102 d](/filings/0001193125-26-349121.md) | [82.0 d](/filings/0001193125-25-280112.md) | [416 d](/filings/0001193125-26-104080.md) | [246](/filings/0001193125-26-221565.md) | [249 d](/filings/0001193125-26-349121.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [8.1](/filings/0001779372-23-000034.md) | [8.2](/filings/0001779372-24-000006.md) | [19.7](/filings/0001628280-24-037202.md) | [26.4](/filings/0001628280-24-046250.md) | [26.5](/filings/0001628280-25-025064.md) | [26.6](/filings/0001628280-25-040135.md) | [26.8](/filings/0001193125-25-280112.md) | [30.4](/filings/0001193125-26-221565.md) | [33.8](/filings/0001193125-26-349121.md) | [34.4](/filings/0001193125-25-280112.md) | [40.6](/filings/0001193125-26-221565.md) | [52.8](/filings/0001193125-26-349121.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 56,349,171 at 2026-08-11, from the cover of the [10-Q filed 2026-08-13](/filings/0001193125-26-349121.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:47 ET. No prices; not investment advice.